Rejuvenate Biomed has enrolled 198 patients in a Phase 2 trial of RJx-01, a multi-pathway therapeutic targeting COPD-induced sarcopenia through mitochondrial function, inflammation, and fibrosis. This represents the first pharmacological approach to sarcopenia, a condition that accounts for substantial disability and frailty in aging populations and currently lacks approved treatments.
Key Points
- RJx-01 addresses three distinct mechanisms: mitochondrial dysfunction, inflammation, fibrosis simult
- Phase 2 trial enrolled 198 patients across Europe; results expected end of 2026
- Early data show both molecular and functional improvements in muscle strength and performance
Longevity Analysis
Sarcopenia sits at the intersection of fundamental aging biology and clinically actionable disease, making it a rational entry point for anti-aging therapeutics into mainstream medicine. A multi-pathway approach that improves mitochondrial health, reduces inflammatory signaling, and restores neuromuscular function addresses the actual complexity of muscle deterioration rather than targeting single points of failure. Whether functional gains in strength and endurance persist and translate to meaningful improvements in resilience and independence will determine whether this model reshapes how we understand and treat age-related decline.
Original published by Longevity.Technology, by Eleanor Garth.